Sugi Predict

Sugi Predict / Compounds / SCHEMBL239179

SCHEMBL239179

SCHEMBL239179

C[Si](C)(c1ccccc1)[Si](C)(C)c1ccccc1

nearest known ligand 0.48

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
▸ ESR1 P03372 1/20 0.48
▸ ESR2 Q92731 1/20 0.48
▸ TSHR P16473 3/20 0.39
▸ ACHE P22303 2/20 0.39
▸ LMNA P02545 1/20 0.39
▸ ALOX12 P18054 1/20 0.39
▸ NR1H2 P55055 2/20 0.38
▸ NR1H3 Q13133 2/20 0.38
▸ MAPT P10636 1/20 0.37
▸ ALDH1A1 P00352 1/20 0.35
▸ NPC1 O15118 3/20 0.35
▸ RAB9A P51151 3/20 0.35
▸ SMN1; SMN2 Q16637 2/20 0.35
▸ TP53 P04637 1/20 0.33
▸ CES2 O00748 1/20 0.33
▸ CES1 P23141 1/20 0.33
▸ MAPK1 P28482 1/20 0.33
▸ CA4 P22748 1/20 0.33
▸ CHEK1 O14757 1/20 0.32
▸ AKT2 P31751 1/20 0.32

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL9340348 0.87 ESR1 (0.44) ESR1ESR2TSHRACHELMNA
SCHEMBL23532344 0.87 ESR1 (0.44) ESR1ESR2TSHRACHELMNA
SCHEMBL11023990 0.87 ESR1 (0.44) ESR1ESR2TSHRACHELMNA
SCHEMBL244122 0.84 ESR1 (0.42) ESR1ESR2TSHRACHELMNA
SCHEMBL10150936 0.84 ESR1 (0.42) ESR1ESR2TSHRACHELMNA
SCHEMBL14163939 0.84 ESR1 (0.74) ESR1ESR2LMNANR1H2NR1H3
SCHEMBL10616290 0.82 ESR1 (0.41) ESR1ESR2TSHRACHELMNA
SCHEMBL10355215 0.82 ESR1 (0.41) ESR1ESR2TSHRACHELMNA
SCHEMBL8214590 0.82 ESR1 (0.41) ESR1ESR2TSHRACHELMNA
SCHEMBL9757676 0.82 ESR1 (0.46) ESR1ESR2TSHRACHELMNA

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 184 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-20230253626-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2023-08-10 — — US claimed
US-11688881-B2 Nonaqueous electrolytic solution and nonaqueous electrolytic solution secondary battery using same MITSUBISHI CHEMICAL CORPORATION (JP) 2023-06-27 — — US claimed
US-20200144670-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2020-05-07 — — US claimed
EP-2672560-B1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME MITSUBISHI CHEM CORP (JP) 2019-10-02 — — EP claimed
US-9806375-B2 Nonaqueous electrolytic solution and nonaqueous electrolytic solution secondary battery using same MITSUBISHI CHEMICAL CORPORATION (JP) 2017-10-31 — — US claimed
CN-103608962-B Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same 三菱化学株式会社 2016-10-26 — — CN claimed
US-9216952-B2 Process for preparing antiviral compound ABBVIE INC. (US) 2015-12-22 — — US claimed
CN-104362371-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same MITSUBISHI CHEM CORP 2015-02-18 — — CN claimed
US-20140363735-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2014-12-11 — — US claimed
EP-2411372-B1 PROCESS FOR PREPARING AN ANTIVIRAL COMPOUND ABBVIE BAHAMAS LTD (BS) 2014-07-23 — — EP claimed
CN-103608962-A Nonaqueous electrolyte solution and nonaqueous electrolyte secondary battery using same MITSUBISHI CHEM CORP 2014-02-26 — — CN claimed
EP-2672560-A1 NON-AQUEOUS ELECTROLYTIC SOLUTION, AND NON-AQUEOUS ELECTROLYTE SECONDARY BATTERY USING SAME Mitsubishi Chemical Corporation (JP) 2013-12-11 — — EP claimed
US-20130309564-A1 NONAQUEOUS ELECTROLYTIC SOLUTION AND NONAQUEOUS ELECTROLYTIC SOLUTION SECONDARY BATTERY USING SAME MITSUBISHI CHEMICAL CORPORATION (JP) 2013-11-21 — — US claimed
US-20110237793-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ABBOTT LABORATORIES (US) 2011-09-29 — — US claimed
EP-0614916-B1 Process for producing polyolefin IDEMITSU PETROCHEMICAL CO (JP) 1998-10-07 — — EP claimed
US-5605990-A USING CATALYST COMPRISING TITANIUM COMPOUND, ALUMINOXANE, AROMATIC RING-CONTAINING COMPOUND IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1997-02-25 — — US claimed
EP-0614916-A1 Process for producing polyolefin IDEMITSU PETROCHEMICAL CO., LTD. (JP) 1994-09-14 — — EP claimed
US-5268232-A Metathesis ring opening polymerization using catalyst HERCULES INCORPORATED (US) 1993-12-07 — — US claimed
US-4952708-A REACTING SUBSTITUTED AROMATIC ACID HALIDES WITH SUBSTITUTED DI-OR POLYSILANES USING TRANSITION METAL COMPLEX AS CATALYST GENERAL ELECTRIC COMPANY (US) 1990-08-28 — — US claimed
EP-0339455-A2 Process for preparing biaryl compounds GENERAL ELECTRIC COMPANY (US) 1989-11-02 — — EP claimed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20110237793-A1 PROCESS FOR PREPARING ANTIVIRAL COMPOUND ZC3HAV1, HAVCR2, MAVS ESR1 4107/4885ESR2 4631/4885TSHR 4663/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.